The review article, “The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action and In Vivo and...
Read MoreNorfolk, VA, January 6th, 2022 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer is...
Read MoreMyeloperoxidase activity in individuals with Anti-neutrophil cytoplasmic antibodies (ANCA) can be inhibited by RLS-0071 At the 2021 Annual Conference of...
Read MoreNorfolk, VA, November 2, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer, will...
Read MoreNorfolk, VA, September 22, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer and...
Read MoreNorfolk, VA, September 22, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer and John...
Read MoreID Week – New Intestinal Necrosis Data Dr. Parvathi Kumar, ReAlta’s Associate Director of Early Clinical Development, will be presenting...
Read MoreRLS-0071 is in development for treatment of Acute Lung Injury (ALI) and Hypoxic Ischemic Encephalopathy (HIE) Norfolk, VA, June 8,...
Read MoreThe Virginian Pilot A Norfolk biotech startup researching treatments for a serious side effect of COVID-19 recently received another funding...
Read More